Update on Regulatory Status of Hypertension, Biomarkers and Arrhythmia Monitoring in Clinical Trials. Join us at FDA White Oak Campus to examine proarrhythmia, hypertension and biomarkers.
In Session 1, leading industry professionals will speak on panels discussing:
In Session 2, the following topics will be discussed:
In Session 3, the meeting faculty will dive into:
In Session 4, the panelists will discuss hot topics in the field such as:
We will be joined by professionals from FDA Regulatory, Cardiac Safety Consultants, Ltd., Eli Lilly, Richmond Pharmacology, University of Connecticut, Stanford University, University of Pennsylvania, Cleveland Clinic, Clario, Mass General, DSI, Penn Medicine, and UCSF.
Our CEO Jorg Taubel will be presenting on the topic of alternative methods for assay sensitivity assessment in routine Phase 1 QT Studies, as well as taking part in a panel about Proarrhythmia.
.svg){kind=small}
.avif)
